Doctors Hospital Health System Limited Interim report Quarter ended October 31, 2024

Chairman's Report Doctors Hospital Health System Limited

Dear Shareholder,

On behalf of the Board of Directors of Doctors Hospital Health System, I report on your company's financial results for the nine months ended October 31, 2024.

Consolidated net profit for the nine months was \$2,941,248 compared to a profit of \$7,302,365 for the comparable period in 2023. Consolidated net patient services revenue increased \$3,853,890 or 4.54% over the 3rd quarter last year. The increase in revenue is primarily a result of the uptick in outpatient activity, combined with a decline in the inpatient admissions. There was an increase of \$4,911,510 or 66.53% on net patient services revenue from the outpatient facilities. Total inpatient days for the nine months ended October 31, 2024 were 7,997 compared to 10,794 the year prior, a reduction of 2,797 days or 25,91%.

Consolidated expenses rose by \$8,120,654 or 9.96%, over the comparable period last year. The increase was driven primarily by increases in personnel cost, medical supplies and other operating expenses, combined with a decrease in provision for doubtful accounts as delineated below:

- Higher salaries and benefits: Increased \$6,604,277 or 19,11% over the 3rd quarter last year. During the year the Group increased its headcount as operations were expanded with the opening of additional facilities in New Providence and Grand Bahama as well as increases in employee benefits borne by the Group.
- Higher medical supplies: Increased \$3,837,341 or 52.08% compared to the same period in 2023. The increase in this expense is a result of adjustments made to medical supplies inventory during the prior year, combined with the increased utilization of supplies due to the additional outpatient locations.
- Higher other operating expenses: Increased \$1,307,561 or 24.22% over the 3rd quarter last year. The primary driving factor for this expense is the number of locations increased, the expenses relating to operations also increased.
- Lower bad debt expense: Decreased \$3,550,047 or 61.14% compared to the same period last year. The Group made changes to its collection process which drove a reduction in the loss rates on its portfolio of receivables, which is reflected in the decrease in the provision for doubtful accounts in the current fiscal year when compared to the prior fiscal year.

On a consolidated basis, return on sales (net income margin) dropped to 3.18% for the nine months ended October 31, 2024, a decline of 61.36% compared to the same period last year. This decrease was driven primarily by the decline in inpatient admissions, which impacted net patient service revenues.

The Board and Management team thank you, our valued shareholders, Physicians, and all Associates for your continued support and loyalty to the Health System. We look forward to continuing to provide an excellent customer experience to our patients and visitors whose loyalty we also appreciate and value.

Felix Stubbs Chairman March 31, 2025

Consolidated Statement of Financial Position

October 31, 2024 with comparative figures at January 31, 2024 (Expressed in thousands of Bahamian dollars)

	Octob	per 31, 2024	January 31, 2024
Assets			
Current assets:			
Cash and cash equivalents	\$	_	1,981
Trade receivables, net (note 2)	,	46,752	42,041
Inventories		6,684	6,470
Prepaid expenses & other assets		3,285	4,343
		56,721	54,835
Non-current assets:		,	
Other assets		598	539
Investments		6,792	7,097
Investment property		915	955
Goodwill, net		3,758	431
Other intangible assets		240	246
Right of use assets		3,570	3,759
Property, plant and equipment		79,186	62,678
		95,059	75,705
Total assets	\$	151,780	130,540
Total assets	Ψ	101,700	130,310
Liabilities and Chambaldam? Emiter			
Liabilities and Shareholders' Equity			
Current liabilities:	Ф	2.015	
Bank overdraft	\$	2,815	10.060
Accounts payable and other liabilities		29,693	19,868
Lease liabilities, current portion		1,647	1,447
Long-term debt, current portion		354	262
		34,509	21,577
Long-term liabilities:			
Lease liabilities		2,169	2,571
Long-term debt		14,300	7,693
		16,469	10,264
Total liabilities		50,978	31,841
Shareholders' equity:			
Share capital:			
Authorized 18,750,000 common shares at par value			
of B\$0.04 each (January 31, 2024 – 18,750,000 shares)			
Issued and fully paid 11,971,634 shares			
(January 31, 2024 – 11,971,634 shares)		479	479
Contributed surplus		25,778	25,778
Retained earnings		74,545	72,442
reamed earnings		100,802	98,699
Total liabilities and shareholders' equity	•	151,780	130,540
Total liabilities and shareholders' equity	\$	151,/80	130,340

Consolidated Statement of Comprehensive Income

Three months ended October 31, 2024 with comparative figures for the three months ended October 31, 2023 (Expressed in thousands of Bahamian dollars)

		er 31, 2024	October 31, 2023	
Revenues				
Patient service revenue, net	\$	28,776	26,197	
Other		704	1,230	
Total revenues		29,480	27,427	
Expenses				
Salaries and benefits		14,193	11,194	
Medical supplies		3,530	3,471	
Medical services		3,002	2,874	
Bad debt expense, net of recoveries		(209)	1,776	
Depreciation and amortization		1,332	1,122	
Other operating		2,263	2,121	
Utilities		870	742	
Government taxes and fees		422	697	
Contracted services		1,488	916	
Insurance		713	340	
Repairs and maintenance		820	986	
Rent		258	155	
Dietary expenses		192	194	
Legal expenses		322	150	
Interest expense		81	73	
Total expenses		29,277	26,811	
Net income & total comprehensive				
income for the period	\$	203	616	
Earnings per common share (expressed in Bahamian dollars):				
Basic and fully diluted	\$	0.02	0.05	

Consolidated Statement of Comprehensive Income

Nine months ended October 31, 2024 with comparative figures for the nine months ended October 31, 2023 (Expressed in thousands of Bahamian dollars)

		er 31, 2024	October 31, 2023	
Revenues				
Patient service revenue, net	\$	88,673	84,819	
Other		1,804	4,002	
Total revenues		90,477	88,821	
Expenses				
Salaries and benefits		41,171	34,567	
Medical supplies		11,206	7,369	
Medical services		8,959	9,460	
Bad debt expense, net of recoveries		2,256	5,806	
Depreciation and amortization		4,509	3,355	
Other operating		6,706	5,398	
Utilities		2,369	2,188	
Government taxes and fees		1,521	2,218	
Contracted services		3,087	6,245	
Insurance		1,953	1,372	
Repairs and maintenance		1,997	2,004	
Rent		238	341	
Dietary expenses		500	689	
Legal expenses		721	271	
Interest expense		343	236	
Total expenses		87,536	81,519	
Net income & total comprehensive				
income for the period	\$	2,941	7,302	
Earnings per common share (expressed in Bahamian dollars):				
Basic and fully diluted	\$	0.25	0.61	
Dasic and fully unuted	Þ	0.25	0.61	

Consolidated Statement of Changes in Equity

Nine months ended October 31, 2024 (Expressed in thousands of Bahamian dollars)

	Number of shares	Share capital	Contributed surplus	Retained earnings	Total
Balance at January 31, 2024	11,971,634	\$ 479	\$ 25,778	\$ 72,442	\$ 98,699
Net income for the period	_	_	_	2,941	2,941
Dividends paid	_	_	_	(838)	(838)
Balance at October 31, 2024	11,971,634	\$ 479	\$ 25,778	\$ 74,588	\$ 100,802

Consolidated Statement of Cash Flows

Nine months ended October 31, 2024 with comparative figures for the nine months ended October 31, 2023 (Expressed in thousands of Bahamian dollars)

	October 31, 2024	October 31, 2023	
CASH FLOWS FROM OPERATING ACTIVITIES:			
Net income	\$ 2,941	7,302	
Adjustments to reconcile net income to net cash	4 –9	.,	
provided by operating activities:			
Depreciation and amortization	4,509	3,355	
Provision for doubtful accounts	2,256	5,806	
Interest income	(263)	(252)	
Interest expense	343	239	
Operating income before working capital changes	9,786	16,450	
Increase in accounts receivable	(8,310)	(15,945)	
Increase in inventories	(214)	(2,660)	
Decrease in prepaid expenses and other assets	999	636	
Increase in accounts payable and other liabilities	9,825	6,920	
Cash generated from operating activities	12,086	5,401	
Interest paid	(343)	(239)	
Net cash from operating activities	11,743	5,162	
CASH FLOWS FROM INVESTING ACTIVITIES:			
Purchase of property, plant and equipment, net	(21,011)	(24,377)	
Purchase of intangible assets, net	(=1,011)	(3)	
Maturity of investments, net	(84)	(116	
Interest received	285	484	
Net cash used in investing activities	(20,810)	(24,012)	
CASH FLOWS FROM FINANCING ACTIVITIES:			
Repayment of long-term debt	(195)	(144)	
Issuance of long-term debt	6,594	5,000	
Lease liabilities, net	(1,290)	(870)	
Dividends paid to shareholders	(838)	_	
Net cash from financing activities	4,271	3,986	
Decrease in cash and cash equivalents	(4,796)	(14,864)	
Cash and cash equivalents at beginning of period	1,981	18,172	
Cash and cash equivalents at end of period	\$ (2,815)	3,308	

Cash and cash equivalents comprise cash at bank and in hand, and short-term deposits with an original maturity of three months or less.

Notes to Interim Consolidated Financial Statements

Nine months ended October 31, 2024

1. Significant accounting policies

These interim financial statements have been prepared in accordance with International Accounting Standard No. 34, Interim Financial Reporting; using the same accounting policies applied in the January 31, 2024 audited consolidated financial statements.

2. Accounts receivable

Accounts receivable are stated net of provisions for doubtful accounts of \$15.4 million.